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Angiotensin II (ATII) levels are elevated in the my-
ocardium after myocardial damage independent of
serum levels [1]. ATII results in an increase NAD(P)H
vascular oxidase, the most important vascular source
of reactive oxygen species (ROS); destruction of nitric
oxide (NO); endothelial dysfunction; vascular inflamma-
tion; vascular remodeling; myocardial hypertrophy and
collagen formation; the progression of atherosclerosis;
atherosclerotic plaque instability; thrombosis and im-
paired fibrinolysis. All of the adverse effects of ATII
appear to be mediated through the AT1 receptor and
can be prevented by angiotensin converting enzyme
inhibitors (ACE-I) or angiotensin receptor antagonists
(ARB’s) providing a strong scientific basis for the clin-
ical use of ACE-I or ARB’s in patients with acute my-
ocardial infarction (MI).
A meta analysis of all randomized trials of ACE-Is
post MI [2] suggests that a relatively uniform beneficial
effect on mortality/morbidity occurs in all subgroups in-
cluding age, gender, baseline use of aspirin, beta block-
ers, and reperfusion status. The valiant trial [3] compar-
ing the ACE-I captopril to the ARB valsartan showed
that blocking the AT1 receptor by valsartan was as ef-
fective as inhibiting the conversion of Angiotensin I to
ATII by captopril. Inhibition or blockade of ATII post
MI has been suggested to be beneficial regardless of the
extent of myocardial damage and the time from onset of
MI, although the benefits appear greater in those early
post MI with signs of heart failure and or a reduced left
ventricular ejection fraction (LVEF) [2].
It is therefore surprising, that Voors et al. [4] in a
pooled analysis of three randomized placebo controlled
trials of ACE-I use within 9 hours of onset of mainly
a first anterior MI find that although ACE-I reduce
the 3 month incidence of hospitalization for HF they
double the 3 month re-infarction rate from 3.6 to 7.0%,
p = 0.032. In those with a relatively large MI and a
reduced LVEF the favorable effects of ACE-Is on ven-
tricular remodeling appear to outweigh the risks of re-
infarction. However, in those with a relatively small
MI the risk or re-infarction appears to outweigh the
benefits such that the net effect is unfavorable. Of in-
terest was their observation that the incidence of re-
infarction post MI was related to ACE-I induced hy-
potension. Hypotension post MI could trigger ischemia,
platelet activation, and thrombosis. Patients with rel-
atively small MIs often have multiple areas of jeop-
ardized myocardium aside from their infarct related
artery. These areas of jeopardized myocardium are
served by narrowed arteries or collateral vessels. Per-
fusion pressure beyond the narrowed artery or collat-
eral vessel is lower than systemic blood pressure. A
drop in systemic blood pressure of only a few mmHg
could therefore trigger myocardial ischemia with all
of its adverse consequences including re-infarction and
possibly sudden cardiac death. Hypotension might also
explain the failure of valsartan to add to the benef-
ical effects of captopril post MI in the valiant trial
[3].
Thus, the observation that ACE-Is increase the inci-
dence of re-infarction when given early post MI is scien-
tifically plausible and could have an important impact
upon our current approach to treating patients early
post MI. However, before altering our current approach
it might be useful to carefully review the basis for the
findings of Voors et al. [4]. The definition of re-infarction
in the studies they reviewed was not prospectively de-
termined but left to individual investigators. One would
have hoped for a prospectively defined definition based
upon a re-elevation of troponin. Thus, while scientifi-
cally plausible the authors observations will require fur-
ther confirmation by a prospective randomized study
before their hypothesis is proven. However, while I will
continue to use an ACE-I or an ARB in the early hours
post MI, especially in patients with evidence of HF and
or a low LVEF, I will be more cautious and would start
with a low dose of captopril, especially in patients with a
borderline systemic blood pressure and in those with a
relatively small MI, and only up-titrate to target doses
of captopril or switch to a longer acting ACE-I or ARB if
blood pressure is maintained over the first 24–48 hours.
The observations of Voors et al. [4] also suggest careful
attention to the effect of any therapeutic agent on blood
pressure considered for use during the early hours post
MI.
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